dilmapimod   Click here for help

GtoPdb Ligand ID: 7815

Synonyms: SB-681323
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This is Example 64 in patent EP1333833 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 99.75
Molecular weight 456.14
XLogP 4.06
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OCC(Nc1nc(c2ccc(cc2C)F)c2c(n1)n(c(=O)cc2)c1c(F)cccc1F)CO
Isomeric SMILES OCC(Nc1nc(c2ccc(cc2C)F)c2c(n1)n(c(=O)cc2)c1c(F)cccc1F)CO
InChI InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)
No information available.
Summary of Clinical Use Click here for help
SB-681323 has been assessed to Phase 2 in clinical trial for indications including chronic obstructive pulmonary disease, rheumatoid arthritis and neuropathic pain, although there are no currently active trials (as of Nov 2014). Click here to view the list of completed SB-681323 trials at ClinicalTrials.gov.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The molecular target of dilmapimod is p38 MAPK.